

# Joanne Barnes Weidhaas

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4835590/joanne-barnes-weidhaas-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87  
papers

6,489  
citations

33  
h-index

80  
g-index

93  
ext. papers

7,079  
ext. citations

8.1  
avg, IF

5.34  
L-index

#	Paper	IF	Citations
87	Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5652-7	2.2	824
86	A SNP in a let-7 microRNA complementary site in the KRAS 3'UTR increases non-small cell lung cancer risk. <i>Cancer Research</i> , <b>2008</b> , 68, 8535-40	10.1	536
85	The let-7 microRNA reduces tumor growth in mouse models of lung cancer. <i>Cell Cycle</i> , <b>2008</b> , 7, 759-64	4.7	534
84	Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. <i>Molecular Therapy</i> , <b>2011</b> , 19, 1116-22	11.7	531
83	Regression of murine lung tumors by the let-7 microRNA. <i>Oncogene</i> , <b>2010</b> , 29, 1580-7	9.2	423
82	Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, E1695-704	11.5	385
81	MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. <i>Cancer Research</i> , <b>2007</b> , 67, 11111-6	10.1	339
80	microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. <i>Cancer Research</i> , <b>2009</b> , 69, 5970-7	10.1	294
79	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , <b>2010</b> , 42, 880-4	36.3	210
78	The mir-34 microRNA is required for the DNA damage response in vivo in <i>C. elegans</i> and in vitro in human breast cancer cells. <i>Oncogene</i> , <b>2009</b> , 28, 2419-24	9.2	192
77	MicroRNA in cancer prognosis. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 2720-2	59.2	151
76	A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. <i>Cancer Research</i> , <b>2010</b> , 70, 6509-15	15.1	122
75	A 3'UTR KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. <i>Lancet Oncology</i> , <b>2011</b> , 12, 377-86	21.7	107
74	Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 908-14	4.6	100
73	A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7723-31	12.9	91
72	MicroRNAs: tools for cancer diagnostics. <i>Gut</i> , <b>2009</b> , 58, 1546-54	19.2	91
71	MicroRNA signatures differentiate melanoma subtypes. <i>Cell Cycle</i> , <b>2011</b> , 10, 1845-52	4.7	81

70	MicroRNA signatures differentiate uterine cancer tumor subtypes. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 251-7	4.9	77
69	miRNA modulation of the cellular stress response. <i>Future Oncology</i> , <b>2008</b> , 4, 289-98	3.6	76
68	SNPping cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. <i>Pharmacology &amp; Therapeutics</i> , <b>2013</b> , 137, 55-63	13.9	75
67	A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. <i>EMBO Molecular Medicine</i> , <b>2012</b> , 4, 206-17	12	70
66	Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2466-73	2.2	66
65	MicroRNAs as a potential magic bullet in cancer. <i>Future Oncology</i> , <b>2006</b> , 2, 73-82	3.6	65
64	A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. <i>Oncogene</i> , <b>2012</b> , 31, 4559-66	9.2	64
63	Cancer microRNAs: from subtype profiling to predictors of response to therapy. <i>Trends in Molecular Medicine</i> , <b>2011</b> , 17, 235-43	11.5	60
62	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4499-4510	12.9	44
61	miR-34 activity is modulated through 5S end phosphorylation in response to DNA damage. <i>Nature Communications</i> , <b>2016</b> , 7, 10954	17.4	42
60	MicroRNA binding site polymorphisms as biomarkers of cancer risk. <i>Expert Review of Molecular Diagnostics</i> , <b>2010</b> , 10, 817-29	3.8	42
59	Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. <i>International Journal of Molecular Epidemiology and Genetics</i> , <b>2011</b> , 2, 9-18	0.9	40
58	The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2017</b> , 3, 483-491	13.4	37
57	Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. <i>Cell Cycle</i> , <b>2014</b> , 13, 1030-40	4.7	34
56	Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 697-702	3.1	34
55	Prevalence of the variant allele rs61764370 T>G in the 3' UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 128, 79-84	4.4	33
54	A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 85, 40-6	4	30
53	A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. <i>Oncogene</i> , <b>2011</b> , 30, 1542-50	9.2	30

52	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 274-284	4	29
51	Rare BRCA1 haplotypes including 35JTR SNPs associated with breast cancer risk. <i>Cell Cycle</i> , <b>2011</b> , 10, 90-9	4.7	29
50	A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1829-1836	12.9	27
49	Using microRNAs to understand cancer biology. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 106-7	21.7	27
48	SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. <i>Critical Reviews in Oncogenesis</i> , <b>2013</b> , 18, 327-40	1.3	27
47	Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI Surveillance, Epidemiology, and End Results database. <i>Cancer</i> , <b>2008</b> , 113, 38-47	6.4	26
46	The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e37891	3.7	25
45	A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans. <i>Cancer Research</i> , <b>2006</b> , 66, 10434-8	10.1	23
44	Targeted resequencing of the microRNAome and 35JTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. <i>Oncogene</i> , <b>2015</b> , 34, 2125-37	9.2	21
43	Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. <i>Nucleic Acids Research</i> , <b>2015</b> , 43, 1098-111	20.1	20
42	KRAS alleles: the LCS6 35JTR variant and KRAS coding sequence mutations in the NCI-60 panel. <i>Cell Cycle</i> , <b>2012</b> , 11, 361-6	4.7	20
41	Breast sentinel lymph node dissection before preoperative chemotherapy. <i>Archives of Surgery</i> , <b>2008</b> , 143, 692-9; discussion 699-700		19
40	The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality. <i>Cancer</i> , <b>2018</b> , 124, 1673-1681	6.4	18
39	Regulation of autophagy, NF- $\kappa$ B signaling, and cell viability by miR-124 in mutant mesenchymal-like NSCLC cells. <i>Science Signaling</i> , <b>2017</b> , 10,	8.8	17
38	Functional microRNA binding site variants. <i>Molecular Oncology</i> , <b>2019</b> , 13, 4-8	7.9	16
37	Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 11-7	4	15
36	The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. <i>PLoS ONE</i> , <b>2014</b> , 9, e94167	3.7	14
35	Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. <i>International Journal of Gynecological Cancer</i> , <b>2013</b> , 23, 615-21	3.5	14

34	MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. <i>Molecular Diagnosis and Therapy</i> , <b>2010</b> , 14, 335-42	4.5	14
33	Enhancing Career Paths for Tomorrow's Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 52-63	4	13
32	COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. <i>International Journal of Gynecological Cancer</i> , <b>2013</b> , 23, 176-83	3.5	13
31	Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4199-206	12.9	12
30	A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. <i>BMC Cancer</i> , <b>2014</b> , 14, 421	4.8	10
29	MicroRNAs and Cancer <b>2017</b> , 277-286		10
28	Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics. <i>Non-coding RNA</i> , <b>2019</b> , 5,	7.1	9
27	Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. <i>Cell Cycle</i> , <b>2015</b> , 14, 2091-9	4.7	9
26	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , <b>2020</b> , 78, 327-332	10.2	9
25	Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein. <i>Molecular Cancer Research</i> , <b>2016</b> , 14, 1068-1077	6.6	9
24	miRNAs in the spotlight: Making Silent Mutations speak up. <i>Nature Medicine</i> , <b>2011</b> , 17, 934-5	50.5	8
23	MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. <i>Human Pathology</i> , <b>2018</b> , 76, 133-140	3.7	6
22	Radiation therapy oncology group gynecologic oncology working group: comprehensive results. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 956-62	3.5	6
21	Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, e205-e218	3	4
20	KRAS rs61764370 in Epithelial Ovarian Cancer-Letter. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6600; author reply 6601	12.9	4
19	The KRAS-variant and cetuximab response in RTOG 0522.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6000-6000		4
18	A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA. <i>Journal of Radiation Oncology</i> , <b>2014</b> , 3, 371-378	0.7	3
17	The KRAS-variant and treatment response in BATTLE-1.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8135-8135.2		3

16	Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. <i>Practical Radiation Oncology</i> , <b>2019</b> , 9, e257-e265	2.8	2
15	The KRAS-variant and its impact on normal breast epithelial cell biology. <i>Cell Death and Differentiation</i> , <b>2019</b> , 26, 2568-2576	12.7	2
14	Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.. <i>Radiotherapy and Oncology</i> , <b>2022</b> , 167, 226-232	5.3	2
13	Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. <b>2022</b> , 10,		2
12	Association of the 3' untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6016-6016	2.2	2
11	Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 786	5.3	1
10	Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 166, 145-156	4.4	1
9	Association between KRAS rs61764370 and triple-negative breast cancer false positive? □ Authors Srepy. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 724	21.7	1
8	Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1	3.1	1
7	Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study. <i>Gynecologic and Obstetric Investigation</i> , <b>2019</b> , 84, 575-582	2.5	0
6	KRAS-LCS6 Genotype as a Prognostic Marker in Early-Stage CRC Response. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3489-3489	12.9	
5	Genomic biomarkers to predict outcome in Gleason Score 9-10 disease.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 44-44	2.2	
4	A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 96-96	2.2	
3	Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2055, 203-212	1.4	
2	Business Development from Research, Entrepreneurship Within Academic Medicine <b>2021</b> , 343-359		
1	Viral Burden and Clearance in Asymptomatic COVID-19 Patients.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac126		1